Display options
Cite
Pinto C, Bergmann M, Briukhovetska D, et al. Sixth Immunotherapy of Cancer conference (ITOC): advances and perspectives-a meeting report. J Immunother Cancer. 2020;8(1)doi: 10.1136/jitc-2019-000268.
Pinto, C., Bergmann, M., Briukhovetska, D., Nuessler, V., Sznol, M., von Bergwelt-Baildon, M., & Kobold, S. (2020). Sixth Immunotherapy of Cancer conference (ITOC): advances and perspectives-a meeting report. Journal for immunotherapy of cancer, 8(1), . https://doi.org/10.1136/jitc-2019-000268
Pinto, Catarina, et al. "Sixth Immunotherapy of Cancer conference (ITOC): advances and perspectives-a meeting report." Journal for immunotherapy of cancer vol. 8,1 (2020). doi: https://doi.org/10.1136/jitc-2019-000268
Pinto C, Bergmann M, Briukhovetska D, Nuessler V, Sznol M, von Bergwelt-Baildon M, Kobold S. Sixth Immunotherapy of Cancer conference (ITOC): advances and perspectives-a meeting report. J Immunother Cancer. 2020 Feb;8(1). doi: 10.1136/jitc-2019-000268. PMID: 32114499; PMCID: PMC7057436.
Copy Download .nbib Format: NLM
Share it on

J Immunother Cancer. 2020 Feb;8(1). doi: 10.1136/jitc-2019-000268.

Sixth Immunotherapy of Cancer conference (ITOC): advances and perspectives-a meeting report.

Journal for immunotherapy of cancer

Catarina Pinto, Michael Bergmann, Daria Briukhovetska, Volkmar Nuessler, Mario Sznol, Michael von Bergwelt-Baildon, Sebastian Kobold

Affiliations

  1. Human Cancer Immunology, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
  2. Department of Surgery, Medical University of Vienna, Vienna, Austria.
  3. Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Klinikum der Ludwig-Maximilians-Universitat Munchen, Munich, Germany.
  4. Tumor Center Munich, Munich, Germany.
  5. Yale Cancer Center, Yale University, New Haven, Connecticut, USA.
  6. Department of Medicine III, Klinikum der Ludwig-Maximilians-Universitat Munchen, Munich, Germany.
  7. German Consortium for Translational Cancer Research (DKTK), Munich, Germany.
  8. Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Klinikum der Ludwig-Maximilians-Universitat Munchen, Munich, Germany [email protected].

PMID: 32114499 PMCID: PMC7057436 DOI: 10.1136/jitc-2019-000268

Abstract

Immunotherapy has moved to the forefront of cancer treatment, illustrated by the accelerating pace of novel therapy approvals. In this complex environment, scientists rely on cutting edge conferences to stay informed. The Immunotherapy of Cancer (ITOC) conference was established jointly with the Society of the Immunotherapy of Cancer to bring the European researchers together. In its sixth edition, the ITOC conference has recently been held in Vienna, Austria.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Keywords: immunology; tumours

Conflict of interest statement

Competing interests: SK has received speakers honorarium from GSK and Novartis. SK has served on the scientific advisory board of Celyad SA and TCR2. SK's research is supported in parts by TCR2.

References

  1. Ann Oncol. 2018 Jan 1;29(1):84-91 - PubMed
  2. Dtsch Med Wochenschr. 2018 Jul;143(14):1006-1013 - PubMed

MeSH terms

Publication Types